Tepotinib is a targeted drug of several generations

Tepotinib (tepotinib) is a third-generation targeted drug that is a tyrosine kinase inhibitor (TKI) and is used for advanced non-small cell lung cancer (NSCLC) containing MET mutations. Tepotinib mainly targets MET gene abnormalities, especially tumors that are positive for MET fusion genes. Compared with earlierTKIs, third-generation TKIs act more precisely on targets, are selective, and can reduce adverse effects on normal cells. This inhibitor is very effective and has central nervous system penetrating activity. Tepotinib also showed partial responses in half of patients with advanced non-small cell lung cancer harboringMET exon 14 skipping mutations.